- Kyowa Kirin raises net income forecast to 68.00 billion yen, up from the initial 63.00 billion yen and exceeding the estimate of 66.56 billion yen.
- Net sales forecast updated to 492.00 billion yen, higher than the previous 473.00 billion yen and above the estimate of 480.3 billion yen.
- Dividend forecast remains unchanged at 58.00 yen, slightly above the estimate of 57.75 yen.
- First half core operating profit reached 44.14 billion yen, marking an 18% increase year over year.
- Second quarter net income soared to 23.15 billion yen, significantly higher than the previous year’s 8.89 billion yen and surpassing the estimate of 16.15 billion yen.
- Second quarter net sales were 127.41 billion yen, representing a 21% year-over-year increase and beating the estimate of 117.16 billion yen.
- Analyst recommendations included 7 buys, 5 holds, and 0 sells.
Kyowa Kirin Co Ltd on Smartkarma
Analyst coverage of Kyowa Kirin Co Ltd on Smartkarma shows positive sentiments regarding recent initiatives to accelerate long-term growth. Tina Banerjee‘s report highlights Kyowa Kirin’s partnership with Bridgebio for infigratinib in Japan and enrolling the first patient in a Phase 2 trial for tivozanib eye drops for DME. Despite higher R&D expenses affecting near-term profit, Kyowa Kirin’s collaboration with Bridgebio on exclusive licenses and the steady growth of its top-selling drug Crysvita are seen as key drivers of future success.
A look at Kyowa Kirin Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Kyowa Kirin Co Ltd is positioned for long-term success. With high marks in Growth, Resilience, and Momentum, the company displays strong potential for expansion, adaptability in changing conditions, and positive market performance. These factors indicate a promising outlook for investors seeking sustainable growth and stability in their portfolio.
Kyowa Hakko Kirin Co.,Ltd., a pharmaceutical company focusing on innovative products like genetically engineered proteins, anti-anemia agents, and glycoproteins, positions itself as a forward-thinking player in the industry. With balanced scores across Value and Dividend factors, Kyowa Kirin Co Ltd proves to be a compelling choice for investors looking for a blend of growth opportunities and income potential in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
